Aurinia Pharmaceuticals (AUPH) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aurinia Pharmaceuticals is set to participate in the Jefferies London Healthcare Conference, engaging with investors through one-on-one meetings and a fireside chat. The company, known for its FDA-approved treatment for lupus nephritis, continues to advance its pipeline with promising therapies for autoimmune diseases.
For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.